Cargando…
Induction of protective immune responses against schistosomiasis using functionally active cysteine peptidases
Each year schistosomiasis afflicts up to 600 million people in 74 tropical and sub-tropical countries, predominantly in the developing world. Yet we depend on a single drug, praziquantel, for its treatment and control. There is no vaccine available but one is urgently needed especially since praziqu...
Autores principales: | El Ridi, Rashika, Tallima, Hatem, Dalton, John P., Donnelly, Sheila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021144/ https://www.ncbi.nlm.nih.gov/pubmed/24847355 http://dx.doi.org/10.3389/fgene.2014.00119 |
Ejemplares similares
-
Induction of Protective Immune Responses Against Schistosomiasis haematobium in Hamsters and Mice Using Cysteine Peptidase-Based Vaccine
por: Tallima, Hatem, et al.
Publicado: (2015) -
Cysteine Peptidases as Schistosomiasis Vaccines with Inbuilt Adjuvanticity
por: El Ridi, Rashika, et al.
Publicado: (2014) -
Increased hepatic interleukin-1, arachidonic acid, and reactive oxygen species mediate the protective potential of peptides shared by gut cysteine peptidases against Schistosoma mansoni infection in mice
por: Tallima, Hatem, et al.
Publicado: (2023) -
Specific Antibodies and Arachidonic Acid Mediate the Protection Induced by the Schistosoma mansoni Cysteine Peptidase-Based Vaccine in Mice
por: Tallima, Hatem, et al.
Publicado: (2020) -
Protective immune responses against Schistosoma mansoni infection by immunization with functionally active gut-derived cysteine peptidases alone and in combination with glyceraldehyde 3-phosphate dehydrogenase
por: Tallima, Hatem, et al.
Publicado: (2017)